BACKGROUND: To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin's lymphoma (NHL) and to identify associated risk factors. PATIENTS AND METHODS: A retrospective analysis included 135 consecutive patients who had been treated with the CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) regimen as first-line therapy between 1994 and 2000. The cardiac evaluation was based on a determination of the resting left ventricular ejection function (LVEF) by gated blood-pool imaging. Cardiotoxicity was defined as a significant decrease in LVEF or clinical evidence of congestive heart failure (CHF). RESULTS: Twenty-seven (20%) patients developed a cardiac event within 1 year of treatment. Among these, 14 patients had clinical signs of CHF. Three patients died suddenly from presumed cardiac causes. In multivariate analysis, a cumulative dose of doxorubicin >200 mg/m(2) [odds ratio (OR) = 4.2, P = 0.005)] and age over 50 years (OR = 2.9, P = 0.03) appeared to be significant risk factors. CONCLUSION: Early clinical and subclinical cardiotoxicity was frequent in patients receiving the CHOP regimen. The threshold of the cumulative dose of doxorubicin appeared to be low: at doses >200 mg/m(2), 27% of patients had cardiac events. Elderly patients appeared to be at higher risk. The development of cardioprotective strategies or alternative treatments are mandatory for aggressive NHL patients.
BACKGROUND: To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin's lymphoma (NHL) and to identify associated risk factors. PATIENTS AND METHODS: A retrospective analysis included 135 consecutive patients who had been treated with the CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) regimen as first-line therapy between 1994 and 2000. The cardiac evaluation was based on a determination of the resting left ventricular ejection function (LVEF) by gated blood-pool imaging. Cardiotoxicity was defined as a significant decrease in LVEF or clinical evidence of congestive heart failure (CHF). RESULTS: Twenty-seven (20%) patients developed a cardiac event within 1 year of treatment. Among these, 14 patients had clinical signs of CHF. Three patients died suddenly from presumed cardiac causes. In multivariate analysis, a cumulative dose of doxorubicin >200 mg/m(2) [odds ratio (OR) = 4.2, P = 0.005)] and age over 50 years (OR = 2.9, P = 0.03) appeared to be significant risk factors. CONCLUSION: Early clinical and subclinical cardiotoxicity was frequent in patients receiving the CHOP regimen. The threshold of the cumulative dose of doxorubicin appeared to be low: at doses >200 mg/m(2), 27% of patients had cardiac events. Elderly patients appeared to be at higher risk. The development of cardioprotective strategies or alternative treatments are mandatory for aggressive NHLpatients.
Authors: P Schütt; K Zimmermann; C Derks; P Ebeling; A Welt; M Poser; J Hense; K Metz; J Anhuf; M Sandmann; M Neise; T Moritz; M Stuschke; N Niederle; S Seeber; Mohammad R Nowrousian Journal: J Cancer Res Clin Oncol Date: 2008-08-29 Impact factor: 4.553
Authors: Hoshang Farhad; Pedro V Staziaki; Daniel Addison; Otavio R Coelho-Filho; Ravi V Shah; Richard N Mitchell; Balint Szilveszter; Siddique A Abbasi; Raymond Y Kwong; Marielle Scherrer-Crosbie; Udo Hoffmann; Michael Jerosch-Herold; Tomas G Neilan Journal: Circ Cardiovasc Imaging Date: 2016-12 Impact factor: 7.792
Authors: Evangelos K Oikonomou; Sofia G Athanasopoulou; Polydoros N Kampaktsis; Damianos G Kokkinidis; Christos A Papanastasiou; Attila Feher; Richard M Steingart; Kevin C Oeffinger; Dipti Gupta Journal: Oncologist Date: 2018-03-28
Authors: John F Seymour; Michael Pfreundschuh; Marek Trnĕný; Laurie H Sehn; John Catalano; Eva Csinady; Nicola Moore; Bertrand Coiffier Journal: Haematologica Date: 2014-06-03 Impact factor: 9.941
Authors: William D Hedrich; Jingwei Xiao; Scott Heyward; Yao Zhang; Junran Zhang; Maria R Baer; Hazem E Hassan; Hongbing Wang Journal: Mol Cancer Ther Date: 2016-01-28 Impact factor: 6.261